Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gyros and Tekon Biotech Sign Distribution Agreement

Published: Tuesday, April 01, 2014
Last Updated: Monday, March 31, 2014
Bookmark and Share
Tekon will distribute Gyros’ immunoassay platform in China, Taiwan & Hong Kong.

Gyros AB has announced that it has appointed Tekon Biotech as exclusive distributor of its nanoliter-scale immunoassay platform Gyrolab™ xP in China, Taiwan & Hong Kong. Tekon Biotech is a leading distributor to pharmaceutical, biotechnology and academic laboratories.

Gyros’ immunoassay platform (www.gyros.com) is used by major biopharmaceutical companies and their service providers worldwide to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.

The platform comprises Gyrolab xP workstation, control and evaluation software, and the unique microfluidic Gyrolab Bioaffy CDs in which immunoassay steps are integrated and run at nanoliter scale.

“We are impressed with Tekon’s reputation for service and technical support in the region, and with a customer base including all major pharmaceutical and biotechnology companies in China, as well as the top 50 universities, Tekon is an ideal partner,” said Dan Calvo, CEO, Gyros AB. “The acceptance of our nanoliter-scale immunoassay platform continues to grow within the global biopharmaceutical industry, and we are delighted that Tekon will be helping to build our network of customers in China, Taiwan and Hong Kong.”

“We are excited to represent Gyros in China," said David Hadfield, CEO, Tekon Biotech in Shanghai. “With the tremendous growth in Biologics in China, plus increased demand for PK/PD and ADA testing, we see great potential for the Gyrolab platform and it’s advances in miniaturized, automated immunoassays.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services
Gyros AB announced that BioAgilytix Labs has invested in two Gyrolab™ xP workstations to support its bioanalysis services.
Tuesday, November 12, 2013
Dan Calvo Appointed CEO of Gyros AB
Erik Walldén steps down as chief executive officer and president.
Thursday, October 24, 2013
Gyros AB Quality Management System Receives ISO 9001:2008 Certification
Certification reassures customers that they receive consistently high standard of products and services.
Tuesday, December 18, 2012
Gyros Expands Asian Distribution to Singapore
Nanoliter-scale immunoassay platform now available to biopharmaceutical companies in Singapore region.
Thursday, June 07, 2012
Gyros and GE Healthcare Life Sciences Expand Asian Distribution Relationship
Gyros AB announces that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong.
Friday, August 26, 2011
Gyros and GE Healthcare Life Sciences Sign Distribution Agreement
Gyros AB announces that GE Healthcare Life Sciences has become the sole distributor for the company’s nanoliter-scale immunoassay platform in Japan.
Tuesday, July 12, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!